Prevalence of fetal ethanol exposure in a regional population-based sample by meconium analysis of fatty acid ethyl esters

Therapeutic Drug Monitoring

Volumn 30, Issue 2, 2008, Pages 239-245

  Gareri, Joey ^a,b   Lynn, Hazel ^c   Handley, Maureen ^c   Rao, Chitra ^a   Koren, Gideon ^a,b  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c Grey Bruce Health Unit   (Canada)

Author keywords

Fatty acid ethyl esters (FAEE); Fetal alcohol spectrum disorder (FASD); Meconium; Neonatal toxicology; Screening

Indexed keywords

BIOLOGICAL MARKER; FATTY ACID ESTER;

CANADA; CONFERENCE PAPER; CONFIDENCE INTERVAL; DATA ANALYSIS; DIAGNOSTIC ACCURACY; FETAL ALCOHOL SYNDROME; HUMAN; LIQUID LIQUID EXTRACTION; MASS FRAGMENTOGRAPHY; MECONIUM; PRENATAL EXPOSURE; PREVALENCE; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; PUERPERIUM; QUESTIONNAIRE; SELF REPORT; SOLID PHASE EXTRACTION; STATISTICAL SIGNIFICANCE;

BIOLOGICAL MARKERS; CANADA; ESTERS; FATTY ACIDS; FEMALE; FETAL ALCOHOL SYNDROME; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; INFANT, NEWBORN; MECONIUM; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; PREVALENCE; SENSITIVITY AND SPECIFICITY;

EID: 42049089307     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/FTD.0b013e318167cfe5     Document Type: Conference Paper

References (39)

1. U.S. Institute of Medicine. Fetal alcohol syndrome: diagnosis, epidemiology, prevention and treatment. In: Stratton K, Howe C, Battaglia F, eds. Fetal Alcohol Syndrome. Washington, DC: National Academy Press; 1996.
2. Streissguth AP, Barr H, Kogan J, et al. Understanding the Occurrence of Secondary Disabilities in Clients with Fetal Alcohol Syndrome (FAS) and Fetal Alcohol Effects (FAE). University of Washington School of Medicine: Fetal Alcohol and Drug Unit, Department of Psychiatry and Behavioral Sciences; 1996 Aug 1.
3. Sampson PD, Streissguth AP, Bookstein FL, et al. Incidence of fetal alcohol syndrome and prevalence of alcohol-related neurodevelopmental disorder. Teratology. 1997;56:317-326.
4. Abel EL. An update on incidence of FAS: FAS is not an equal opportunity birth defect. Neurotoxicol Teratol. 1995;17:437-443.
5. Russell M, Martier SS, Sokol RJ, et al. Detecting risk drinking during pregnancy: a comparison of four screening questionnaires. Am J Public Health. 1996;86:1435-1439.
6. Stoler JM, Huntington KS, Peterson CM, et al. The prenatal detection of significant alcohol exposure with maternal blood markers. J Pediatr. 1998;133:346-252.
7. Swift R. Direct measurement of alcohol and its metabolites. Addiction. 2003;98(Suppl 2):73-80.
8. Kwong TC, Ryan RM. Detection of intrauterine illicit drug exposure by newborn drug testing. National Academy of Clinical Biochemistry. Clin Chem. 1997;43:235-242.
9. Miller V, Holzel A. Growth and development of endodermal structures. In: Davis J, Dobbing J, eds. Scientific Foundations in Paediatrics. Philadelphia: WB Saunders; 1974:281-296.
10. Chan D, Klein J, Koren G. New methods for neonatal drug screening. NeoReviews. 2004;4:e1-e8.
11. Abusada GM, Abukhalaf IK, Alford DD, et al. Solid-phase extraction and GC/MS quantitation of cocaine, ecgonine methyl ester, benzoylecgonine, and cocaethylene from meconium, whole blood, and plasma. J Anal Toxicol. 1993;17:353-358.
12. Chan D, Bar-Oz B, Pellerin B, et al. Population baseline of meconium fatty acid ethyl esters among infants of nondrinking women in Jerusalem and Toronto. Ther Drug Monit. 2003;25:271-278.
13. Koren G, Chan D, Klein J, et al. Estimation of fetal exposure to drugs of abuse, environmental tobacco smoke, and ethanol. Ther Drug Monit. 2002;24:23-25.
14. Moore C, Jones J, Lewis D, et al. Prevalence of fatty acid ethyl esters in meconium specimens. Clin Chem. 2003;49:133-136.
15. Chan D, Caprara D, Blanchette P, et al. Recent developments in meconium and hair testing methods for the confirmation of gestational exposures to alcohol and tobacco smoke. Clin Biochem. 2004;37:429-438.
16. Bearer CF, Jacobson JL, Jacobson SW, et al. Validation of a new biomarker of fetal exposure to alcohol. J Pediatr. 2003;143:463-469.
17. Bearer CF, Gould S, Emerson R, et al. Fetal alcohol syndrome and fatty acid ethyl esters. Pediatr Res. 1992;31:492-495.
18. Bearer CF, Lee S, Salvator AE, et al. Ethyl linoleate in meconium: a biomarker for prenatal ethanol exposure. Alcohol Clin Exp Res. 1999;23:487-493.
19. Klein J, Karaskov T, Korent G. Fatty acid ethyl esters: a novel biologic marker for heavy in utero ethanol exposure: a case report. Ther Drug Monit. 1999;21:644-646.
20. Yamashita T, Lee SC, Minnew S, et al. Meconium FAEE and maternal ethanol use [Abstract]. Alcohol Clin Exp Res. 1997;21:119A.
21. Best CA, Laposata M. Fatty acid ethyl esters: toxic non-oxidative metabolites of ethanol and markers of ethanol intake. Front Biosci. 2003;8:e202-e217.
22. Werner J, Saghir M, Warshaw AL, et al. Alcoholic pancreatitis in rats: injury from nonoxidative metabolites of ethanol. Am J Physiol Gastrointest Liver Physiol. 2002;283:G65-G73.
23. Laposata EA, Lange LG. Presence of nonoxidative ethanol metabolism in human organs commonly damaged by ethanol abuse. Science. 1986;231:497-499.
24. Chan D, Knie B, Boskovic R, et al. Placental handling of fatty acid ethyl esters: perfusion and subcellular studies. J Pharmacol Exp Ther. 2004;310:75-82.
25. Alcohol use among women of childbearing age - United States, 1991-1999. MMWR Morb Mortal Wkly Rep. 2002;51:273-276.
26. Centers for Disease Control. Alcohol consumption among women who are pregnant or who might become pregnant - United States, 2002. MMWR Morb Mortal Wkly Rep. 2004;53:1178-1181.
27. Chavez GF, Cordero JF, Becerra JE. Leading major congenital malformations among minority groups in the United States, 1981-1986. MMWR CDC Surveill Summ. 1988;37:17-24.
28. Sokol RJ, Clarren SK. Guidelines for use of terminology describing the impact of prenatal alcohol on the offspring. Alcohol Clin Exp Res. 1989;13:597-598.
29. Sampson PD, Bookstein FL, Barr HM, et al. Prenatal alcohol exposure, birthweight, and measures of child size from birth to age 14 years. Am J Public Health. 1994;84:1421-1428.
30. Williams RJ, Odaibo FS, McGee JM. Incidence of fetal alcohol syndrome in northeastern Manitoba. Can J Public Health. 1999;90:192-194.
31. Statistics Canada. Canadian Community Health Survey. Ottawa: Statistics Canada; 2001. Report No. Cycle 1.1.
32. Fisher DA. Neonatal thyroid screening. Pediatr Clin North Am. 1978;25:423-429.
33. Zaffanello M, Maffeis C, Zamboni G. Multiple positive results during a neonatal screening program: a retrospective analysis of incidence, clinical implications and outcomes. J Perinat Med. 2005;33:246-251.
34. Waisbren SE, Doherty LB, Bailey IV, et al. The New England Maternal PKU Project: identification of at-risk women. Am J Public Health. 1988;78:789-792.
35. Pepler D, Moore T, Motz M, et al. Breaking the Cycle: A Chance for New Beginnings. 1995-2000 Evaluation Report. Toronto: Breaking the Cycle; 2002.
36. Poole P. Evaluation Report of the Sheway Project for High-Risk Pregnant and Parenting Women. Vancouver: British Columbia Centre of Excellence for Women's Health; 2000.
37. Leonardson GR, Loudenburg R. Risk factors for alcohol use during pregnancy in a multistate area. Neurotoxicol Teratol. 2003;25:651-658.
38. Loeber G, Webster D, Aznarez A. Quality evaluation of newborn screening programs. Acta Paediatr Suppl. 1999;88:3-6.
39. Hermeren G. Neonatal screening: ethical aspects. Acta Paediatr Suppl. 1999;88:99-103.